Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Description

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Conditions

Psoriasis

Talk to us

Study Overview

On this page

Study Details

Study overview

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Condition
Psoriasis
Intervention / Treatment

-

Contacts and Locations

East Windsor

Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States, 08520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Male or female adult ≥ 18 years of age;
  • * Diagnosis of chronic plaque-type
  • * Patient with 2-10% BSA
  • * Physician Global Assessment of 2 or greater
  • * Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
  • * ˂2 or \>10% BSA
  • * PGA \<2
  • * Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Psoriasis Treatment Center of Central New Jersey,

Study Record Dates

2019-12-15